HBRI is proud to have supported Clover Biopharmaceuticals in the successful completion of their Phase 1 clinical study interim analysis evaluating RSV-hMPV±PIV3combination vaccines. The study’s positive outcomes were shared on Wednesday, 15 October at the World Vaccine Congress 2025 in Amsterdam, The Netherlands.
HBRI provided end-to-end sample testing services against hMPV and PIV3 viruses under tight timelines. From project initiation to data delivery, the Cerba team demonstrated agility and cross-functional coordination to ensure that the study results were ready in time for presentation at the congress.
“Delivering this level of scientific excellence within such a short timeframe requires tremendous dedication and teamwork,” said Joëlle Vink, Project Manager at HBRI. “Every function, from Business Development and Research & Development to Operations and Project Management, worked as one team to make this possible. We are extremely proud of what we achieved together.”
Clover’s decision to entrust HBRI with this study was based on the company’s proven scientific expertise, high-quality assays, and strong track record in vaccine development. During the execution phase, HBRI teams successfully accelerated key processes without compromising data quality or integrity. The smooth collaboration between both organizations ensured efficient communication, rapid data transfer, and reliable scientific outcomes that supported Clover’s presentation at one of the most prestigious global vaccine events.
“This project illustrates what HBRI stands for: scientific rigor, operational excellence, and a shared commitment to advancing global health,” said Maria Fotiu, CEO of HBRI. “We are honored to see our work contribute to innovative vaccine programs that may help protect vulnerable populations from respiratory infections.”
HBRI warmly thanks Clover Biopharmaceuticals for their recognition and trust. The collaboration exemplifies what can be achieved through scientific partnership and shared purpose, and we look forward to continuing our collaboration in the next phases of this important program.
